NASDAQ:ZEALZEALAND PHARMA/S Stock Price, Forecast & News

$39.06

-1.94 (-4.73 %)

(As of 06/1/2020 03:31 PM ET)

Add

Compare

Today's Range

$39.06

Now: $39.06▼

$39.06

50-Day Range

$31.61

MA: $34.45▼

$37.00

52-Week Range

$18.75

Now: $39.06▼

$44.60

Volume100 shs

Average Volume5,395 shs

Market Capitalization$1.44 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.26

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Beat the Market (BTM) Rank^™

1.4 Analyst's Opinion

Consensus Rating
ZEALAND PHARMA/S has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.00, ZEALAND PHARMA/S has a potential upside of 2.4% from its current price of $39.06.
Amount of Analyst Coverage
ZEALAND PHARMA/S has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
ZEALAND PHARMA/S has received 279 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ZEALAND PHARMA/S has received 282 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ZEALAND PHARMA/S has received 50.27% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ZEALAND PHARMA/S and other stocks. Vote “Outperform” if you believe ZEAL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ZEALAND PHARMA/S does not currently pay a dividend.
Dividend Growth
ZEALAND PHARMA/S does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ZEALAND PHARMA/S insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 6.38% of the stock of ZEALAND PHARMA/S is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for ZEALAND PHARMA/S are expected to decrease in the coming year, from ($3.07) to ($3.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ZEALAND PHARMA/S is -14.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ZEALAND PHARMA/S is -14.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ZEALAND PHARMA/S has a P/B Ratio of 6.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.78 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZEAL

Previous Symbol

CUSIPN/A

CIK1674988

Webwww.zealandpharma.com

Phone45-8877-3600

Debt

Debt-to-Equity Ratio0.08

Current Ratio7.30

Quick Ratio7.30

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6.20 million

Price / Sales232.60

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.85 per share

Price / Book6.68

Profitability

EPS (Most Recent Fiscal Year)($2.54)

Net Income$-85,670,000.00

Net Margins-1,157.20%

Return on Equity-51.41%

Return on Assets-40.71%

Miscellaneous

Employees149

Outstanding Shares36,920,000

Market Cap$1.44 billion

Next Earnings Date8/20/2020 (Estimated)

OptionableNot Optionable

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

ZEALAND PHARMA/S (NASDAQ:ZEAL) Frequently Asked Questions

How has ZEALAND PHARMA/S's stock been impacted by COVID-19 (Coronavirus)?

ZEALAND PHARMA/S's stock was trading at $28.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZEAL shares have increased by 39.0% and is now trading at $39.06. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ZEALAND PHARMA/S?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZEALAND PHARMA/S in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ZEALAND PHARMA/S.

When is ZEALAND PHARMA/S's next earnings date?

ZEALAND PHARMA/S is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for ZEALAND PHARMA/S.

How were ZEALAND PHARMA/S's earnings last quarter?

ZEALAND PHARMA/S (NASDAQ:ZEAL) released its earnings results on Thursday, May, 14th. The company reported ($4.98) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $4.35. The company earned $1.83 million during the quarter, compared to the consensus estimate of $5.13 million. ZEALAND PHARMA/S had a negative net margin of 1,157.20% and a negative return on equity of 51.41%. View ZEALAND PHARMA/S's earnings history.

What price target have analysts set for ZEAL?

5 equities research analysts have issued 1-year price objectives for ZEALAND PHARMA/S's shares. Their forecasts range from $37.00 to $42.00. On average, they anticipate ZEALAND PHARMA/S's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View analysts' price targets for ZEALAND PHARMA/S.

Has ZEALAND PHARMA/S been receiving favorable news coverage?

Media coverage about ZEAL stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ZEALAND PHARMA/S earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutZEALAND PHARMA/S.

Who are some of ZEALAND PHARMA/S's key competitors?

Some companies that are related to ZEALAND PHARMA/S include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Emergent Biosolutions (EBS), PPD (SDGR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI), GW Pharmaceuticals PLC- (GWPH) and Biohaven Pharmaceutical (BHVN). View all competitors.

What other stocks do shareholders of ZEALAND PHARMA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZEALAND PHARMA/S investors own include GALAPAGOS NV/S (GLPG), Eyepoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Zymeworks (ZYME), AbbVie (ABBV), Protalix Biotherapeutics (PLX) and SCYNEXIS (SCYX).

Who are ZEALAND PHARMA/S's key executives?

ZEALAND PHARMA/S's management team includes the following people:

Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Director (Age 66)
Dr. Emmanuel Dulac Ph.D., PharmD, MBA, CEO & Pres (Age 49)
Mr. Ivan Mourits Møller, Interim CFO and Sr. VP of Technical Devel. & Operations (Age 47)
Dr. Andrew Parker, Exec. VP & Chief Science Officer (Age 54)
Lani Pollworth Morvan, Investor Relations & Communications Officer

When did ZEALAND PHARMA/S IPO?

(ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is ZEALAND PHARMA/S's stock symbol?

ZEALAND PHARMA/S trades on the NASDAQ under the ticker symbol "ZEAL."

Who are ZEALAND PHARMA/S's major shareholders?

ZEALAND PHARMA/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (3.88%), Jane Street Group LLC (0.05%), Morgan Stanley (0.04%), Rockefeller Capital Management L.P. (0.02%) and UBS Group AG (0.00%).

Which major investors are selling ZEALAND PHARMA/S stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, and Rockefeller Capital Management L.P..

Which major investors are buying ZEALAND PHARMA/S stock?

ZEAL stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, UBS Group AG, and Morgan Stanley.

How do I buy shares of ZEALAND PHARMA/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ZEALAND PHARMA/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $39.06.

How big of a company is ZEALAND PHARMA/S?

ZEALAND PHARMA/S has a market capitalization of $1.44 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. ZEALAND PHARMA/S employs 149 workers across the globe.

What is ZEALAND PHARMA/S's official website?

The official website for ZEALAND PHARMA/S is www.zealandpharma.com.

How can I contact ZEALAND PHARMA/S?

ZEALAND PHARMA/S's mailing address is SMEDELAND 36 GLOSTRUP, COPENHAGEN G7, 2600. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff